| 9th Aug 2019 7:00 am |
RNS |
Tagrisso significantly improves overall survival |
| 7th Aug 2019 7:00 am |
RNS |
Lynparza Phase III PROfound trial in HRR* |
| 5th Aug 2019 7:00 am |
RNS |
Forxiga label updated in the EU in type-2 diabetes |
| 1st Aug 2019 3:00 pm |
RNS |
Total Voting Rights |
| 25th Jul 2019 7:00 am |
RNS |
AZN: H1 2019 Results |
| 15th Jul 2019 7:00 am |
RNS |
Update on US regulatory decision for Farxiga |
| 12th Jul 2019 7:00 am |
RNS |
Imfinzi granted US Orphan Drug Designation for |
| 1st Jul 2019 3:00 pm |
RNS |
Total Voting Rights |
| 1st Jul 2019 7:00 am |
RNS |
Forxiga receives positive EU CHMP opinion for |
| 1st Jul 2019 7:00 am |
RNS |
Fasenra receives positive EU CHMP opinion for self |
| 27th Jun 2019 7:00 am |
RNS |
Imfinzi improves overall survival at interim |
| 19th Jun 2019 7:00 am |
RNS |
Breztri Aerosphere (PT010) approved in Japan for |
| 19th Jun 2019 7:00 am |
RNS |
Lynparza approved in Japan for 1st-line |
| 19th Jun 2019 7:00 am |
RNS |
Bevespi Aerosphere approved by the Japanese |
| 18th Jun 2019 7:00 am |
RNS |
Lynparza approved in the EU for 1st-line |
| 17th Jun 2019 7:00 am |
RNS |
Calquence significantly prolonged the time patient |
| 12th Jun 2019 4:45 pm |
RNS |
Publication of a Prospectus |
| 6th Jun 2019 7:00 am |
RNS |
Calquence Phase III ELEVATE-TN trial met primary |
| 5th Jun 2019 12:36 pm |
EQS |
Hardman & Co Research: AstraZeneca: Where has all the cash gone? |
| 3rd Jun 2019 3:00 pm |
RNS |
Block listing Interim Review |
| 3rd Jun 2019 3:00 pm |
RNS |
Total Voting Rights |
| 3rd Jun 2019 7:00 am |
RNS |
Lynparza nearly doubled time patients lived with |
| 10th May 2019 7:00 am |
RNS |
Pooled analyses of the roxadustat global Phase III |
| 8th May 2019 2:00 pm |
RNS |
Director/PDMR Shareholding |
| 8th May 2019 11:00 am |
RNS |
Director Declaration |
| 8th May 2019 7:00 am |
RNS |
Trastuzumab deruxtecan demonstrated clinically |
| 7th May 2019 7:00 am |
RNS |
Calquence PhIII ASCEND trial met primary endpoint |
| 3rd May 2019 7:00 am |
RNS |
Qternmet XR approved in the US for type-2 diabetes |
| 1st May 2019 3:00 pm |
RNS |
Total Voting Rights |
| 1st May 2019 12:00 pm |
RNS |
Director/PDMR Shareholding |
| 29th Apr 2019 7:00 am |
RNS |
Lynparza receives positive EU CHMP opinion for 1st |
| 26th Apr 2019 5:45 pm |
RNS |
Result of AGM |
| 26th Apr 2019 7:00 am |
RNS |
AZN: Q1 2019 Results |
| 10th Apr 2019 7:00 am |
RNS |
Lynparza approved in EU for the treatment of germl |
| 9th Apr 2019 4:10 pm |
EQS |
Hardman & Co Research: Global Pharmaceuticals: 2018 industry sales |
| 4th Apr 2019 1:30 pm |
RNS |
Holding(s) in Company |
| 3rd Apr 2019 10:00 am |
RNS |
Director/PDMR Shareholding |
| 2nd Apr 2019 3:00 pm |
RNS |
Total Voting Rights |
| 1st Apr 2019 6:00 pm |
RNS |
Astrazeneca |
| 1st Apr 2019 3:00 pm |
RNS |
Total Voting Rights |
